A team from the Broad Institute at MIT and Harvard have designed a Cas13–CRISPR construct, termed CARVER, that can detect and kill viruses inside human cells. The flexible CARVER system could be used as a new tool in research and the clinic.
Browsing: Basic > Drug Development
In this interview we speak to Pinaki Panigrahi about his work using probiotics as a preventative strategy against sepsis in neonates. In addition, he comments on the impact of probiotics for other infections and some of the skepticism surrounding some microbiome research.
Take a look at this month’s industry headlines including FDA warnings over hepatitis C drugs in patients with liver injury, a new infectious diseases strategy for the UK and priority review for Merck’s Ebola vaccine.
In this interview, Paul Rowley (University of Idaho, ID, USA) speaks about his research identifying novel antifungal proteins from Saccharomyces cerevisiae yeasts and whether these could be translated into the medications of the future.
In this perspective piece for Future Microbiology the authors argue that there is a lack of innovation to meet the current shortcomings of antibiotic R&D.
Researchers have developed an animal model mimicking HIV infection in infants, potentially allowing the development of therapeutics and interventions for the pediatric population.
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
In this interview we speak to Vincent Racaniello, Professor of Microbiology & Immunology, about his work on polio, picornaviruses and publicizing science through blogs and podcasts.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.